Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor

Journal of Rheumatology

Volumn 30, Issue 3, 2003, Pages 544-549

  Leff, Richard L ^a   Elias, Ileana ^b   Ionescu, Mirela ^c   Reiner, Agnes ^c   Poole, A Robin ^c,d  

^a ASTRAZENECA   (United Kingdom)

^b Aventis Pasteur   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Aggrecan; Cartilage; Clinical trial; Collagen; Matrix metalloproteinase inhibitor; Osteoarthritis

Indexed keywords

AGGRECAN; COLLAGEN TYPE 2; COLLAGENASE; KERATAN SULFATE; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; PROTEOGLYCAN; TANOMASTAT;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ARTICULAR CARTILAGE; ASTHENIA; CARTILAGE BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXTRACELLULAR MATRIX; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; OSTEOARTHRITIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNOVIAL FLUID; URINE RETENTION; VERTIGO;

ADMINISTRATION, ORAL; AGED; AGGRECANS; ANTINEOPLASTIC AGENTS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; LECTINS, C-TYPE; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; ORGANIC CHEMICALS; OSTEOARTHRITIS, KNEE; PROTEOGLYCANS; SYNOVIAL FLUID; TREATMENT OUTCOME;

EID: 0037334432     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dieppe PA. Osteoarthritis: Introduction. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1994:2.1-6.
2. Hough AJ Jr, Sokoloff L. Pathology of osteoarthritis. In: McCarty DJ, editor. Arthritis and allied conditions. A textbook of rheumatology. 11th ed. Philadelphia: Lea and Febiger; 1989:1571.
3. Poole AR. Cartilage in health and disease. In: Koopman W, editor. Arthritis and allied conditions. A textbook of rheumatology. 13th ed. Baltimore: Williams and Wilkins; 1997:255-308.
4. Kuettner K. Osteoarthritis: Cartilage integrity and homeostasis. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1994:1-16.
5. Cawston TE. Proteinases and inhibitors. BMJ 1995;51:385-401.
6. Poole AR, Alini M, Hollander A. Cellular biology of cartilage degradation. In: Henderson B, Pettifer R, Edwards J, editors. Mechanisms and models in rheumatoid arthritis. London: Academic Press; 1995:163.
7. Lark MW, Bayne EK, Falagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106.
8. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
9. Billinghurst RC, O'Brien K, Poole AR, McIlwraith CW. Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor. Ann NY Acad Sci 1999;878:594-7.
10. Altman R, Asch E, Bloch DA, et al. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
11. Bellamy N, Buchanan WW, Goldlsmith CH, Campbell J, Stitt L. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
12. Hollander AP, Heathfield TF, Webber C, et al. Increased damage to type II collagen in osteoarthritic cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32.
13. Nelson F, Dahlberg L, Laverty S, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998;102:2115-25.
14. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992;90:2268-77.
15. Smith GN, Yu L, Brandt, Capello W. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998;25:532-5.
16. Glant TT, Mikecz K, Roughley PJ, Buzas E, Poole AR. Age-related changes in protein-related epitopes of human articular cartilage proteoglycans. Biochem J 1986;236:71-5.